Spectral MD Holdings, Ltd.
("Spectral MD" or the "Company")
Notice of Results
Investor Presentation
LONDON, U.K. AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it will release its full year results for the year ended 31 December 2022 on Monday 27 February 2023.
Investor presentation
Wensheng Fan, Chief Executive Officer, and Nils Windler, Chief Financial Officer, will provide a live presentation relating to the full year results via the Investor Meet Company platform on Monday 27 February 2023 at 4.30 pm GMT.
The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am GMT the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Spectral MD here.
Investors who already follow Spectral MD on the Investor Meet Company platform will automatically be invited.
For further information please contact:
| Spectral MD Holdings, Ltd. | investors.spectralmd.com | ||
| Wensheng Fan, Chief Executive Officer | via Walbrook PR | ||
| Nils Windler, Chief Financial Officer |
| ||
|
|
| ||
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 | ||
| Stuart Gledhill/Harry Davies-Ball (Corporate Finance) Vadim Alexandre/Rob Rees (Sales & Broking)
|
| ||
| Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland Will Palmer-Brown | Tel: +44 (0)20 7710 7600 | ||
|
|
| ||
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | ||
| Paul McManus / Louis Ashe-Jepson / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 +44 (0)7407 804 654 | ||
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.